Received Jul 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 39H2S | — |
A patient could have potentially received only the adjuvant of Shingrix; A patient could have potentially received only the adjuvant of Shingrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 53-year-old male patient who received Herpes zoster (Shingrix) (batch number 39H2S, expiry date 10-MAR-2027) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: A patient could have potentially received only the adjuvant of Shingrix) and inappropriate dose of vaccine administered (Verbatim: A patient could have potentially received only the adjuvant of Shingrix). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 18-JUN-2025 On 18th June 2025, an nurse called to report that they may have accidentally administered only the adjuvant portion of the Shingrix vaccine to 1 out of 7 patients, which led to Inappropriate preparation of medication and Inappropriate dose of vaccine administered. This had been the first dose of Shingrix for all seven patients. At the time, it was unclear whether any form of immunity screening or antibody titers specific to Shingrix were available. It was also uncertain whether all seven patients would need to be revaccinated due to the possible administration of the adjuvant only. This was 1 of the 7 cases, reported by the same reporter.; Sender's Comments: US-GSK-US2025076586:Same reporter/Diffrent patient US-GSK-US2025076590:Same reporter/Diffrent patient US-GSK-US2025076589:Same reporter/Diffrent patient US-GSK-US2025076585:Same reporter/Diffrent patient US-GSK-US2025076593:Same reporter/Diffrent patient